Last reviewed · How we verify

NCT06748261: Atlantis

AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA

Not yet recruiting Last updated 27 December 2024
What this trial tests

trial testing CCTAI model in Cardiovascular Diseases in 5,000 participants. Not yet recruiting.

Timeline
30 December 2024
Primary endpoint
30 June 2025
30 December 2025

Quick facts

Lead sponsorShanghai Zhongshan Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment5,000
Start date30 December 2024
Primary completion30 June 2025
Estimated completion30 December 2025

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Zhongshan Hospital

Who can join

Eligibility, any sex, with Cardiovascular Diseases or Hypertrophic Cardiomyopathy (HCM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational and diagnostic study is to develop and validate an artificial intelligence assisted approach for coronary computer tomography angiography-(CCTA)-based screening and diagnosis of cardiomyopathies in patients with suspected coronary artery diseases. This study aims to develop a computerized CCTA interpretation using artificial intelligence for multi-label classification task to assist cardiomyopathy diagnosis in the clinical workflow.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06748261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing